Top Markets
#1 DogBull DogBull +105.02%
#2 Siacoin Siacoin +50.45%
#3 MarsCoin MarsCoin +49.07%
#4 ADO Protocol ADO Protocol +46.44%
#5 UnifAI Network UnifAI Network +44.79%
#6 Ontology Gas Ontology Gas +25.91%
#7 Useless Coin Useless Coin +23.08%
#8 Magma Finance Magma Finance +22.65%
#9 Cash Cat Cash Cat +16.86%
#10 Apertum Apertum +13.60%
Coin of the day
DogBull DogBull
設定
言語
日本
通貨
USD
テーマ
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
株式のランク #15968
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
株価
$15.42
時価総額
$320.83M
変化（1日）
-1.52%
変化（1年）
40.67%
国
IT
取引 Newron Pharmaceuticals S.p.A. (NP5)

カテゴリー

Healthcare
Newron Pharmaceuticals S.p.A.（NP5）の収益
Sep 2026 時点の収益 TTM: 0
Newron Pharmaceuticals S.p.A. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Newron Pharmaceuticals S.p.A. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH